A Retrospective Study Determining the Association between Echocardiographic LVFP Parameter, VMT Score and Clinical Outcomes of HFpEF
Authors/Creators
- 1. Senior Resident (Academic), Department of Cardiology, IGIMS, PATNA, Bihar, India
- 2. Additional Professor, Department of Cardiology, IGIMS, PATNA, Bihar, India
Description
Aim: The aim of the present study was to determine the association between the newly proposed echocardiographic LVFP parameter, visually assessed time difference between the mitral valve and tricuspid valve opening (VMT) score, and clinical outcomes of HFpEF. Methods: This was a retrospective observational study that assessed the VMT score and clinical outcomes in patients with HFpEF in the Department of Cardiology, IGIMS, PATNA, Bihar, India. 200 patients were included in the study. Results: Out of 200 patients, 36 patients were under VMT0, 130 in VMT1 and 34 in VMT 2 or 3. While LV volume was increased in patients with VMT 2/3, LV wall thickness and EF were similar among the groups, resulting in greater LV mass index and stroke volume in this group. Mitral E wave velocity, E/A, LA volume index, TR pressure gradient, and E/e0 were increased, and the deceleration time of the E wave and LV isovolumic relaxation time were shortened in accordance with the VMT score, resulting in the higher prevalence of elevated LVFP judged by the 2016 ASE/EACVI recommendations in VMT 2/3. There was an increase in the prevalence of significant mitral regurgitation in the higher VMT scores. RV dimensions and RA volume were also increased with the VMT score which could be associated with a higher prevalence of significant TR in VMT 2/3. While RV systolic function was similar between the groups, the VMT 2/3 was characterized by a larger IVC diameter and lower its respiratory change. Conclusion: In patients with HFpEF, the VMT score was independently and incrementally associated with adverse clinical outcomes. Moreover, it could also predict clinical outcomes in HFpEF patients with AF.
Abstract (English)
Aim: The aim of the present study was to determine the association between the newly proposed echocardiographic LVFP parameter, visually assessed time difference between the mitral valve and tricuspid valve opening (VMT) score, and clinical outcomes of HFpEF. Methods: This was a retrospective observational study that assessed the VMT score and clinical outcomes in patients with HFpEF in the Department of Cardiology, IGIMS, PATNA, Bihar, India. 200 patients were included in the study. Results: Out of 200 patients, 36 patients were under VMT0, 130 in VMT1 and 34 in VMT 2 or 3. While LV volume was increased in patients with VMT 2/3, LV wall thickness and EF were similar among the groups, resulting in greater LV mass index and stroke volume in this group. Mitral E wave velocity, E/A, LA volume index, TR pressure gradient, and E/e0 were increased, and the deceleration time of the E wave and LV isovolumic relaxation time were shortened in accordance with the VMT score, resulting in the higher prevalence of elevated LVFP judged by the 2016 ASE/EACVI recommendations in VMT 2/3. There was an increase in the prevalence of significant mitral regurgitation in the higher VMT scores. RV dimensions and RA volume were also increased with the VMT score which could be associated with a higher prevalence of significant TR in VMT 2/3. While RV systolic function was similar between the groups, the VMT 2/3 was characterized by a larger IVC diameter and lower its respiratory change. Conclusion: In patients with HFpEF, the VMT score was independently and incrementally associated with adverse clinical outcomes. Moreover, it could also predict clinical outcomes in HFpEF patients with AF.
Files
IJTPR,Vol14,Issue4,Article32 (4).pdf
Files
(408.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:aaf2fd77f2d22f2646f85f3da7377fd0
|
408.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-20
Software
References
- 1. Braunwald E, Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's heart disease: a textbook of cardiovascular medicine. InBraunwald's heart disease: A textbook of cardiovascular medicine 2015 (pp. 1028-1028). 2. Redfield MM. Heart failure--an epidemic of uncertain proportions. N Engl J Med. 2002 Oct 31;347(18):1442-4. 3. Remme WJ, McMurray JJ, Rauch B, Zannad F, Keukelaar K, Cohen-Solal A, Lopez-Sendon J, Hobbs FD, Grobbee DE, Boccanelli A, Cline C, Macarie C, Dietz R, Ruzyllo W. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J. 2005 Nov;26 (22):2413-21. 4. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex: American Heart Association; 2005. 5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20;112(12):e154-235. 6. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006 Jun 20; 113(24):2851-60. 7. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, LopezSendon JL, Nieminen MS, Piérard L, Remme WJ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005 Jun;26(11): 1115-40. 8. Oh JK. Echocardiography in heart failure: beyond diagnosis. Eur J Echocardiogr. 2007 Jan; 8(1):4-14. 9. Picano E. Sustainability of medical imaging. BMJ. 2004 Mar 6;328(7439):578-80. 10. Picano E. Economic and biological costs of cardiac imaging. Cardiovasc Ultrasound. 2005 May 25; 3:13. 11. European Commission on Radiation protection 118: Referral guidelines for imaging. 12. International Commission on Radiation Protection . Radiation and your patient: a guide for medical practitioners. A web module produced by Committee 3 of the International Commis- sion on Radiological Protection. United Kingdom: Pergamon Press; 2001. 13. International Commission on Radiological Protection. Radiological protection in Biomedical Research. United Kingdom: Pergamon Press; 1991. 14. Harada T, Obokata M, Omote K, Iwano H, Ikoma T, Okada K, Yoshida K, Kato T, Kurosawa K, Nagai T, Negishi K. Independent and incremental prognostic value of semiquantitative measures of tricuspid regurgitation severity in heart failure with preserved ejection fraction. European Heart Journal-Cardiovascular Imaging. 2021 Dec 1;22(12):1443-51. 15. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Journal of Echocardiography. 2016 Jul 15; 17 (12):1321-60. 16. Murayama M, Iwano H, Nishino H, Tsujinaga S, Nakabachi M, Yokoyama S, Aiba M, Okada K, Kaga S, Sarashina M, Chiba Y. Simple twodimensional echocardiographic scoring system for the estimation of left ventricular filling pressure. Journal of the American Society of Echocardiography. 2021 Jul 1;34(7):723-34. 17. Pellicori P, Shah P, Cuthbert J, Urbinati A, Zhang J, Kallvikbacka‐Bennett A, Clark AL, Cleland JG. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. European journal of heart failure. 2019 Jul;21(7):904-16. 18. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006 Jul 20;355(3):251-9. 19. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. New England Journal of Medicine. 2006 Jul 20;355(3):260-9. 20. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014 Sep;11(9):507-15. 21. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology. 2019 Dec 10;74(23):2858-73. 22. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circulation: Heart Failure. 2010 Sep;3(5):588-95. 23. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, Neumann FJ. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. European heart journal. 2014 Nov 21;35(44):3103-12. 24. Rethy L, Borlaug BA, Redfield MM, Oh JK, Shah SJ, Patel RB. Application of guidelinebased echocardiographic assessment of left atrial pressure to heart failure with preserved ejection fraction. Journal of the American Society of Echocardiography. 2021 May 1;34(5): 455-64. 25. Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, openlabel, single-arm, phase 1 trial. The Lancet. 2016 Mar 26;387(10025):1298-304. 26. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014 Nov;7(6):935-44.